Skip to content

Lilly Plans to Sell Covid-19 Antibody Directly to Health-Care Providers

  • Sale to public will require change in authorization: Lilly
  • Government’s suppy has diminished as funding dries up

Eli Lilly & Co. plans to sell its Covid-19 antibody directly to health providers, states and territories in a bid to keep the drug available even as US government funding and purchases dry up. 

The US is working with Lilly to allow it to sell the antibody, bebtelovimab, through commercial channels, representatives for the Indianapolis-based drugmaker and the Health and Human Services Department said Wednesday. The government’s supply of the therapy will run out as early as the week of Aug. 22, according to Lilly spokeswoman Dani Barnhizer.